About Decheng Capital

Decheng Capital is a leading investment firm that provides capital and strategic support to early stage life science companies with revolutionary technologies and growth stage healthcare companies with strong market presence. We are a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.




November 10, 2020
Exclusive: Decheng's Inside View of Merck's $2.75 Billion Acquisition of VelosBio

November 5, 2020
Merck to buy VelosBio for $2.75 billion to bolster oncology pipeline

October 13, 2020
Cue Receives $481 Million Award by DOD and HHS to Expand Domestic Production Capacity and Provide 6 Million Molecular, Point-of-Care COVID-19 Tests

October 12, 2020
Exclusive: How Sequencing Firm ReadCoor Came to be Acquired by 10x Genomics

October 9, 2020
Everest Medicines Raises $423 million in Hong Kong IPO

October 7, 2020
Mammoth Biosciences Founder, Professor Jennifer Doudna, Wins 2020 Nobel Prize in Chemistry

October 5, 2020
10x Genomics to Acquire ReadCoor for $350M

September 23, 2020
Exclusive: The Story Behind How Cirina, a $12 Million Hong Kong Diagnostics Startup, Became Part of Illumina

September 21, 2020
Illumina to Acquire GRAIL for $8 billion to Launch New Era of Cancer Detection

August 6, 2020
Checkmate Pharma Raises $75 Million IPO

July 28, 2020
Sema4 Closes $121 Million Series C

July 8, 2020
VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology

June 25, 2020
Polares Medical Closes a $40M Financing to Complete Pilot Clinical Studies

June 18, 2020
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101

June 12, 2020
Cue Health Receives FDA Emergency Use Authorization for Its Rapid, Portable, Molecular Point-of-Care COVID-19 Test

June 10, 2020
Cue Health Closes $100 Million Series C Financing to Support Launch of Rapid Molecular Testing Platform

June 10, 2020
Checkmate Pharmaceuticals Secures $85 Million in Series C Financing

June 4, 2020
Everest Medicines Completes US$310 Million Series C Financing

Copyright © 2011 Decheng Capital LLC. All Rights Reserved.